What Next for MEDRELEAF CORP ORDINARY SHARES CANADA (OTCMKTS:MEDFF) Stock After Increase in Shorted Shares?

May 10, 2018 - By Marguerite Chambers

The stock of MEDRELEAF CORP ORDINARY SHARES CANADA (OTCMKTS:MEDFF) registered an increase of 1.53% in short interest. MEDFF’s total short interest was 271,300 shares in May as published by FINRA. Its up 1.53% from 267,200 shares, reported previously. With 221,000 shares average volume, it will take short sellers 1 days to cover their MEDFF’s short positions. The short interest to MEDRELEAF CORP ORDINARY SHARES CANADA’s float is 2.72%.

The stock decreased 0.09% or $0.0159 during the last trading session, reaching $18.1041. About 105,250 shares traded. MedReleaf Corp. (OTCMKTS:MEDFF) has 0.00% since May 10, 2017 and is . It has underperformed by 11.55% the S&P500.

MedReleaf Corp. produces and sells cannabis pharmaceutical products in Canada. The company has market cap of $1.84 billion. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. It currently has negative earnings.

More notable recent MedReleaf Corp. (OTCMKTS:MEDFF) news were published by: Midasletter.com which released: “VIDEO: UIT Fund Manager Charles Taerk on CannTrust Holdings Inc, Cronos Group, and MedReleaf Corp” on April 13, 2018, also Midasletter.com with their article: “CannTrust Holdings Inc Soars As Cannabis Investors Shift Focus to Mid-Major Market” published on May 04, 2018, Midasletter.com published: “MedReleaf Corp (TSE:LEAF) Surges As Technical Breakout is Confirmed” on May 01, 2018. More interesting news about MedReleaf Corp. (OTCMKTS:MEDFF) were released by: Profitconfidential.com and their article: “Is This the Beginning of a Move Toward Higher MedReleaf Stock Prices?” published on April 18, 2018 as well as Profitconfidential.com‘s news article titled: “Your $1000 Investment in Canopy Growth Stock Would Have Made You $13k Richer in Just 3 Years” with publication date: May 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: